Benepali® PEN Patient Satisfaction Survey
Launched by BIOGEN · Oct 26, 2017
Trial Information
Current as of August 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Diagnosis of moderate to severe active rheumatoid arthritis, severe active and progressive rheumatoid arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis, or severe non-radiographic axial spondyloarthritis
- • Current treatment with the Benepali® pre-filled pen in accordance with prescribing information for at least 3 months beforehand
- • The patient has signed a declaration of consent to take part in the study
- Key Exclusion Criteria:
- • Patients who are receiving Benepali® for the treatment of moderate to severe plaque psoriasis
- • Patients who exhibit contraindications in accordance with the prescribing information for Benepali® and therefore treatment with Benepali ® is not indicated
- • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
About Biogen
Biogen is a leading biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a strong focus on research and development, Biogen leverages advanced science and cutting-edge technology to address the unmet needs of patients suffering from conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company is committed to advancing the understanding of the underlying biology of these diseases and is actively engaged in clinical trials to evaluate new treatment options, aiming to improve patient outcomes and enhance quality of life. With a global presence and a robust pipeline of therapies, Biogen is at the forefront of innovation in the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin, , Germany
Düsseldorf, , Germany
Ulm, , Germany
Giessen, , Germany
Magdeburg, , Germany
Erfurt, , Germany
Leipzig, , Germany
Coburg, , Germany
Homburg, , Germany
Kronach, , Germany
München, , Germany
Bad Neuenahr Ahrweiler, , Germany
Nürnberg, , Germany
Altenholz, , Germany
Braunschweig, , Germany
Dresden, , Germany
Ehringshausen, , Germany
Essen, , Germany
Göpping, , Germany
Halle, , Germany
Hamburg, , Germany
Jülich, , Germany
Köln, , Germany
Ludwigshafen, , Germany
Mansfeld, , Germany
Mittelherwigsdorf, , Germany
Neuss, , Germany
Norderstedt, , Germany
Offenberg, , Germany
Saarbrücken, , Germany
Seesen, , Germany
Tübingen, , Germany
Patients applied
Trial Officials
Medical Director
Study Director
Biogen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials